Beta Bionics, Inc. (BBNX) Spending and interest coverage
- R&D / revenue · 12 months: Value 32.70%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 17.82%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 32.70% | Research and development expense / revenue. Period ending 2026-06-30. $38.92M ÷ $119.01M × 100 ≈ 32.70% |
| Stock-based compensation / revenue · 12 months | 17.82% | Share-based compensation / revenue. Period ending 2026-06-30. $21.20M ÷ $119.01M × 100 ≈ 17.82% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 38.92M USD | Research and Development Expense |
| Revenue | 119.01M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 21.20M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -83.02M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $38.92M | $119.01M | $21.20M | $-83.02M | (m) | 32.70% | 17.82% | (m) | (m) |
| 2026-03-31 | $37.55M | $110.24M | $18.99M | $-77.31M | (m) | 34.07% | 17.22% | (m) | (m) |
| 2025-12-31 | $34.79M | $100.25M | $16.38M | $-71.68M | (m) | 34.70% | 16.34% | (m) | (m) |
| 2025-09-30 | $33.87M | $88.57M | $13.63M | $-68.59M | (m) | 38.24% | 15.39% | (m) | (m) |
| 2025-06-30 | $30.82M | $78.02M | $11.13M | $-62.53M | (m) | 39.50% | 14.27% | (m) | (m) |
| 2025-03-31 | $28.30M | $69.83M | $7.83M | $-54.44M | (m) | 40.52% | 11.21% | (m) | (m) |
| 2024-12-31 | $26.18M | $65.12M | $6.38M | $-45.25M | (m) | 40.21% | 9.80% | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $17.94M | $11.99M | $5.66M | $-35.85M | (m) | 149.59% | 47.17% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |